Welcome to our dedicated page for iRhythm Holdings SEC filings (Ticker: IRTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The iRhythm Technologies, Inc. (NASDAQ: IRTC) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a public issuer. As a digital health care company focused on ambulatory cardiac monitoring and data analytics, iRhythm uses its SEC reports to communicate financial performance, risk factors, governance matters, and material corporate events related to its Zio long-term continuous monitoring (LTCM) service and broader operations.
Investors can use this page to review current and historical filings retrieved from the SEC’s EDGAR system, including annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K. Recent 8-K filings have covered topics such as quarterly financial results, investor presentations, and amendments to the Executive Change in Control and Severance Policy, which outlines severance payments, COBRA coverage, and equity vesting treatment for senior leaders under specified termination scenarios.
For those analyzing iRhythm’s business in more depth, the company’s periodic reports typically discuss revenue from Zio services, gross margins, operating expenses, non-GAAP measures like adjusted EBITDA and adjusted net loss, and liquidity metrics such as cash, cash equivalents, and marketable securities. These documents also describe how iRhythm accounts for items like stock-based compensation, business transformation costs, and other adjustments that affect non-GAAP results.
Stock Titan enhances access to these filings with AI-powered summaries that help explain the key points of lengthy documents, such as 10-K and 10-Q reports, in more accessible language. Users can quickly identify major changes in financial condition, updates to risk disclosures, and details of insider or executive-related arrangements that appear in forms and exhibits. This combination of real-time filing access and AI-generated insights can support investors, analysts, and other stakeholders who want to understand how iRhythm reports on its digital cardiac monitoring business and corporate governance over time.
Form 3/A overview: iRhythm Technologies, Inc. (IRTC) filed an amended Form 3 for newly appointed Chief Technology Officer Brian Lee Lawrence. The amendment, dated 06/27/2025, corrects the original 04/21/2025 filing by attaching the Power of Attorney that was previously omitted.
Key points for investors:
- No securities owned: The report states that Mr. Lawrence currently holds zero shares or derivative securities of IRTC.
- Administrative nature: No changes to capital structure, operations, or financial outlook are disclosed; the sole purpose is to provide the missing document.
- Insider alignment: The absence of ownership may indicate limited immediate equity alignment between the CTO and shareholders, although incentive grants can follow after employment begins.
This filing is largely procedural and does not contain material financial information or signal any strategic shift for iRhythm.
Form 4 overview: iRhythm Technologies (IRTC) Chief Financial Officer Daniel G. Wilson disclosed the sale of 3,000 common shares on 06/23/2025 at $150 per share, generating approximately $450,000 in proceeds.
Remaining ownership: After the transaction, Wilson directly owns 40,307 shares. No indirect holdings were reported.
Trade context: The filing states the sale was executed pursuant to a Rule 10b5-1 trading plan adopted on 11/14/2024, which can shield the insider from accusations of timing the market.
No derivative activity: Table II shows no option exercises, grants, or other derivative movements.
Investor takeaways: Insider sales can raise questions about management’s confidence, but the modest size relative to Wilson’s remaining stake and the pre-planned nature reduce negative interpretation. The transaction does not affect the company’s capital structure or operations but provides incremental insight into insider sentiment toward IRTC’s valuation around the $150 level.